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Abstract 
Objective: Atrial fibrillation (AF) is very frequent and clinically significant arrhythmia. The incidence of atrial 
fibrillation is continuously rising. Meanwhile several risk factors for AF development have been identified but the 
etiology is not cleared.  
Methods: A systematic review and re-analysis of studies which investigated the relationship between AF and 
some risk factors was conducted. The method of the conditio sine qua non relationship, the method of the conditio 
per quam relationship, the method of the exclusion relationship and the mathematical formula of the causal 
relationship k were used to proof the hypothesis. Significance was indicated by a p-value of less than 0.05.  
Results: The studies analyzed were able to provide direct and indirect evidence that AF is caused by a process of 
inflammation while a direct identification of the factor causing AF was not possible. Still, it appears to be very 
probable that Epstein-Barr virus (EBV) is the cause of AF.   
Conclusion: Atrial fibrillation (AF) appears to be caused by an EBV inflammatory process.  
Keywords: Epstein-Barr virus, atrial fibrillation, causal relationship 
1. Introduction 
In general, atrial fibrillation (AF) is regarded as a disease of the elderly, with a substantially increase (Chugh et al., 
2014) of incidence and prevalence with age but asymptomatic atrial fibrillation (AF) has been detected by 
implanted cardiac devices (Glotzer & Ziegler, 2013) too which is generally undetected in the clinical setting. Thus 
far, more than 10% of the general population older than 80 years suffer from AF. Nonetheless, about 90 % of the 
elderly patients have none AF. Among other measures, long-term use of oral anticoagulants (OACs) for stroke 
prevention for people aged over 75 who have atrial fibrillation is required (Mant et al., 2007). To date, the precise 
mechanisms involved in AF is not well understood. In particular, people who are living healthy lives and have no 
other medical problems develop sometimes atrial fibrillation too. In addition to cardiac causes such as congestive 
heart failure or valve disease other common risk factors (Wasmer et al., 2017) of atrial fibrillation like cigarette 
smoking, diabetes mellitus, hypertension (Kirchhof et al., 2012), prevalent coronary artery disease (Benjamin et al., 
1994) chronic kidney disease (Psaty et al., 1997) have been identified and are regarded as well-established risk 
factors of AF. Less well-established risk factors are alcohol consumption, genetic factors (Fox et al., 2004), left 
atrial (LA) enlargement (Psaty et al, 1997) and other. The diagnosis of AF is secured by an cost-effective 
electrocardiogram (ECG) showing the typical pattern of absolutely irregular RR intervals and no discernible, 
distinct P waves while both symptomatic and asymptomatic episodes of AF (Kirchhof et al., 2009; Savelieva & 
Camm, 2000) must be distinguished. In general, ECG monitoring is of further help for the management of AF. 
Several studies hypothesized even that inflammation (Aviles et al., 2003; Issac et al., 2007; Kirchhof et al., 2013) 
is involved in the pathogenesis and development of AF (Stroke Risk in Atrial Fibrillation Working Group, 2007; 
Cha et al., 2018). 
2. Material and Methods 
2.1 Material 
2.1.1 Search Strategy 
To answer the questions addressed in this paper, the electronic database PubMed was searched for appropriate 
studies conducted in any country which investigated the relationship between atrial fibrillation and inflammation. 
The search in PubMed was performed while using some medical key words atrial fibrillation and virus and 
glucocorticoid et cetera. The articles found where saved as a *.txt file while using the support of PubMed. The 
created *.txt file was converted into a *.pdf file. The abstracts where studied within the *.pdf file. Those articles 
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were considered for a re-view which provided access to data without any data access barrier. Additionally the 
reference list of identified articles was used as a potential source of articles appropriate for this study.  
2.1.2. The 2x2 Table 
The meaning of the abbreviations at, bt, ct, dt, Nt of the data table used are explained by a 2 by 2-table Table 1. 
 
Table 1. The sample space of a contingency table. 
  Conditioned Bt (Outcome)  
  Yes = +1 Not = +0 Total 
Condition At 
(risk factor) 
Yes =+1 at bt At 
Not = +0 ct dt At 
 Total Bt Bt nt 
It is (at+bt) = At, (ct+dt) = At, (at+ct) = B, (bt+dt) = Bt and at+bt+ct+dt=nt. Equally, it is Bt+Bt = At + At = nt.  
 
2.1.3 The Studies Used to Analyze the Conventional Risk Factor 
The table (Table 2) presents the data of some studies which analyzed the relationship between AF and some risk 
factors. The contradictions are signed by red color. 
 
Table 2. The relationship between some classical risk factors and AF. 
Study Id Year Country Risk Factor Case_P Case_T Con_P Con_T k p-val X²(SINE) X²(IMP) X²(IMP^SINE) X²(EXCL)
Wang et al. 2015 China Family history 12 285 11 300 0.01398 0.15872 260.55 4.79 265.34 6.21
Wang et al. 2015 China Alcohol 97 285 89 300 0.04688 0.03726 123.36 42.11 165.46 82.74
Wang et al. 2015 China Smoke 147 285 159 300 -0.01422 0.06220 66.34 82.10 148.44 145.44
Chao et al. 2018 Taiwan Diabetes mellitus 3770 15756 2884 14658 0.0513 3.5E-20 9117.30 1249.56 10366.86 3037.25
Wang et al. 2015 China Diabetes mellitus 86 285 90 300 0.00191 0.0717 138.25 45.51 183.77 67.19
Wang et al. 2015 China Dyslipidemia 117 285 112 300 0.03808 0.04422 98.44 54.29 152.73 106.89
Kim et al. 2014 USA Hyperlipidemia 6439 20852 34561 104260 -0.01801 8.3E-12 9961.64 29132.39 39094.04 2999.10
Kim et al. 2014 USA Hypertension 5876 20852 26360 104260 0.02468 3.4E-19 10755.11 21554.26 32309.38 2726.45
Chao et al. 2018 Taiwan Hypertension 11679 15756 9005 14658 0.13594 4.5E-125 1054.70 3919.99 4974.69 15250.08
Wang et al. 2015 China Hypertension 220 285 221 300 0.04091 0.04701 14.60 110.25 124.85 278.31
Wang et al. 2015 China Cerebral infarction 91 285 82 300 0.05034 0.03448 131.38 38.39 169.77 76.08
Chao et al. 2018 Taiwan Previous stroke/TIA 7772 15756 4724 14658 0.17366 2.1E-203 4045.21 1785.49 5830.69 8666.46
Wang et al. 2015 China Arteriosclerosis 201 285 190 300 0.07636 0.01277 24.46 91.84 116.31 243.87
Chao et al. 2018 Taiwan Prev. vascular disease  2004 15756 5230 14658 -0.2694 0 12002.02 3780.44 15782.45 809.64
Chao et al. 2018 Taiwan Congestive heart failure 8680 15756 3042 14658 0.35252 0 3177.37 789.18 3966.55 11207.97
Kim et al. 2014 USA Cardiovascular disease 1439 20852 5355 104260 0.02902 3.7E-24 18072.37 4220.00 22292.37 403.81
 
Table 3. The relationship between a therapy with (methyl-) prednisolon and permanent AF 
The Study of Dernellis & Panaretou, 2004 
Permanent AF <B>  
Total Yes No 
Methylprednisolone 16 mg Yes 1 15 16 
<A> No 51 37 88 
Total 52 52 104 
k = - 0.3731 
p value (k) = 0.0001 
95% CI (k) = (0.1538;0.5924) 
<A> EXCLUDES  <B> and vice versa  
p(EXCL)= 0.99038462  
X²(EXCL)= 0.0204  
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2.1.4 Methylprednisolone and Permanent AF 
Dernellis & Panaretou (Dernellis & Panaretou, 2004) investigated whether a low-dose glucocorticoid therapy (16 
mg methylprednisolone for 4 weeks tapered to 4 mg for 4 months) compared to placebo is able to reduce AF. 
2.2 Methods  
2.2.1 Statistical Analysis 
All statistical analyses (Barukčć, 1989; Barukčć, 2005; Barukčć, 2006; Barukčć, 2016; Barukčć, 2017; Barukčć, 
2018) were performed with Microsoft Excel version 14.0.7166.5000 (32-Bit) Software (Microsoft GmbH. 
Munich. Germany). The level of significance was set to 0.05. The probabilities of the contingency table are 
viewed by the following table (Table 4).  
 
Table 4. The probabitlities of a contingency table 
  Conditioned Bt  
  Yes = +1 No = +0 Total 
Condition At Yes =+1 p(at) = p(At ∩Bt) p(bt) p(At) No = +0 p(ct) p(dt) p(At) 
 Total p(Bt) p(Bt) 1 
 
In this context, it is p(at)=p(At ∩Bt), p(At) = p(at)+p(bt) or p(At)= p(At ∩Bt)+ p(bt) =p(At ∩Bt)+p(At ∩Bt) while 
p(At) is not defined as p(at). In the same context, it is p(Bt) = p(at)+p(ct) = p(At ∩Bt) +p(ct) and equally in the 
same respect p(Bt) = 1- p(Bt) =p(bt)+p(dt). Furthermore, the joint probability of At and Bt is denoted in general 
by p(At ∩Bt). Thus far, it is p(At ∩Bt) = p(At) - p(bt) = p(Bt) - p(ct) or in other words it follows clearly that p(Bt) 
+ p(bt) - p(ct) = p(At). Thus far, define Λ = p(bt) - p(ct), under conditions of probability theory and we obtain p(Bt) 
+ Λ = p(At). In general, it is p(at)+p(ct)+p(bt)+p(dt) = 1. 
2.2.2 Independence 
In the case of independence of At and Bt (Kolmogoroff, 1933) it is generally valid that 
 
(1) 
2.2.3 Exclusion (At Excludes Bt and Vice Versa Relationship) 
The mathematical formula of the exclusion relationship (At excludes Bt and vice versa) of a population was 
defined (Barukčć, 1989; Barukčć, 2005; Barukčć, 2006; Barukčć, 2016; Barukčć, 2017; Barukčć, 2018) as 
 
(2) 
 
and used to proof the hypothesis: At excludes Bt and vice versa.  
2.2.4 Necessary Condition (Conditio Sine Qua Non) 
The mathematical formula of the necessary condition relationship (conditio sine qua non) of a population was 
defined (Barukčć, 1989; Barukčć, 2005; Barukčć, 2006; Barukčć, 2016; Barukčć, 2017; Barukčć, 2018) as 
 
(3) 
 
and used to proof the hypothesis: without At no Bt .  
2.2.5. Sufficient Condition (Conditio per Quam) 
The mathematical formula of the sufficient condition relationship (conditio per quam) of a population was 
defined (Barukčć, 1989; Barukčć, 2005; Barukčć, 2006; Barukčć, 2016; Barukčć, 2017; Barukčć, 2018) as 
 
(4) 
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and used to proof the hypothesis: if At then Bt .  
2.2.6 The X² Goodness of Fit Test of a Necessary Condition 
Under conditions where the chi-square goodness of fit test (Pearson, 1900) cannot be used it is possible to use an 
approximate and conservative (one sided) confidence interval known as the rule of three (Rumke, 1975; Hanley et 
al., 1983; Louis, 1981; Jovanovic et al., 1997). Using the continuity correction (Yates, 1934), the chi-square value 
of a conditio sine qua non distribution is derived as 
 
 
(5) 
 
2.2.7 The X² Goodness of Fit Test of the Exclusion Relationship 
The chi square value with degree of freedom 2-1=1of the exclusion relationship (Barukčć, 1989; Barukčć, 2005; 
Barukčć, 2006; Barukčć, 2016; Barukčć, 2017; Barukčć, 2018) with a continuity correction (Yates, 1934) can be 
calculated as 
 
ܺଶ ሺܧܺܥܮሻ = ൫−ܽ௧ ൯
ଶ
ܣ௧
 (6)
2.2.8 The Mathematical Formula of the Causal Relationship k 
The mathematical formula of the causal relationship k (Barukčć, 1989; Barukčć, 2005; Barukčć, 2006; Barukčć, 
2016; Barukčć, 2017; Barukčć, 2018) is defined at every single event, at every single Bernoulli trial t, as 
 
(7) 
 
 
where At denotes the cause and Bt denotes the effect. The chi-square distribution can be applied to determine the 
significance of causal relationship k. Pearson’s concept of correlation (Pearson, 1896) is not identical with 
causation, causation is not identical with correlation. In particular, the relationship between correlation and 
causation has already been discussed in many publications (Barukčć, 1989; Barukčć, 2005; Barukčć, 2006; 
Barukčć, 2016; Barukčć, 2017; Barukčć, 2018). Thus far, repeating itself over and over again on this topic is only 
a waste of time and will not contribute anything new to further scientific progress. 
2.2.9 The 95% Confidence Interval of the Causal Relationship k 
A confidence interval (CI) of the causal relationship k calculated from the statistics of the observed data can help to 
estimate the true value of an unknown population parameter with a certain probability. Let the sample mean S be 
 
(8) 
 
Since k(At,Bt) is Bernoulli(p) distributed with E(k(At,Bt)) = (1× p(k(At,Bt))) + (0×(1- p(k(At,Bt))) = p(k(At,Bt)) 
where E(k(At,Bt)) denotes the expected value of k(At,Bt) it is 
 
(9) 
 
where σ(S)² denotes the variance of the sampling distribution of p(k(At,Bt)). When the sample size is not too small, 
the central limit theorem based normal approximation can be used to estimate the confidence interval (CI) as  
 
(10) 
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where p(k(At,Bt)) denotes the proportion of successes in a Bernoulli trial process and Z is the (1–(α/2)) quantile of 
a standard normal distribution. For a 95% confidence level Z ~ 1.96. For an unknown standard deviation the 
Student's t distribution t can be used as the critical value. Still, it is known that σ(S)² has the maximum value 
(1/(4×n)) when p=1/2 and approximately we obtain 
 
(11) 
 
The proposed approximation is of use even under circumstances where p(…) = 0.9999 … 999 ~ p=1.  In this 
context, we obtain the critical value pcritical approximately as pcritical = 1 – (1/(n))1/2.  In particular, the concept of 
Chebyshev’s inequality is profound because the same inequality is true for every distribution even if the 
distribution isn’t normal. Thus far, Chebyshev’s inequality allows calculating the 95% confidence of the causal 
relationship k and so by the Chebyshev inequality it is 
 
(12) 
 
were the right side has the value 0.95 when c =(20)1/2. This is the case since (1-(1/c²))=0.95 or 0.05 = (1/c²) or c²= 
(1/0.05) or c² = (100/5) or c² = 20 or c =(20)1/2. Thus far, if S does lie in the interval 
 
(13) 
 
then p(k(At,Bt)) itself must be in the interval 
 
(14) 
which is equally the 95% confidence interval for an unknown parameter p(k(At,Bt)). Again, σ(S)² has the 
maximum value (1/(4×n)) when p=1/2, so we have  
 
(15) 
 
or the 95% interval for the causal relationship k as 
 
(16) 
 
2.2.10 Hypergeometric distribution  
The probability of having exactly at (Table 1) successes or the significance of the causal relationship k can be 
tested under conditions of sampling without replacement by the hypergeometric distribution as 
 
 
(17) 
 
 
2.2.11 Odds Ratio  
The odds ratio (OR) is given (Barukčć, 2018) by 
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Under conditions were ct=0 there is a conditio sine qua non relationship while the odds ratio collapses. Under 
conditions were bt=0 we have a conditio per quam relationship but the odds ratio collapses again, since to date it is 
not generally accepted (Barukčić & Barukčić, 2016b; Barukčić, 2018d) to divide by zero. To avoid confusion on 
this issue, 0.5 is added to the cells at, bt, ct, dt (Barukčć, 2018), if zero causes some problems with the calculation of 
the odds ratio or its standard error which is often very misleading. In point of fact, the odds ratio (OR) is nothing 
more but Yule’s coefficient of association Q (Barukčć, 2018) re-written (Barukčć, 2018) in a non-normalized form 
and given by 
 
 
(19) 
 
 
If Q = 0 then there is no association. Yule's coefficient of association, Q, and thus far Odds ratio itself, has been 
severely criticized by Karl Pearson (1857–1925), the long-time and rarely challenged leader of statistical science 
and by Heron (Barukčć, 2018). The standard error and 95% confidence interval of the odds ratio (OR) can be 
calculated according to Altman (Altman, 1991). The standard error of the log odds ratio is given by 
 
 (20) 
where ln denotes the logarithmus naturalis. The 95% confidence interval of the odds ratio is given by 
 
(21) 
2.2.12 The unknown population proportion πupper 
Tests of hypotheses concerning the sampling distribution of the sample proportion p (i. e. conditio sine qua non 
p(SINE), conditio per quam p(IMP) et cetera) can be performed using the normal approximation. The calculation 
of the rejection region based on the sample proportion to construct a confidence interval for an unknown 
population proportion πupper can be performed under conditions of sampling without replacement by the formula 
 
(22) 
 
while the term ((N-n)/(N-1)) denotes the finite population correction (Isserlis, 1918). 
2.2.13 The Chi Square Distribution 
The following critical values of the chi square distribution as visualized by Table 5 are used in this publication. 
 
Table 5. The critical values of the chi square distribution (degrees of freedom: 1) 
  p-Value One sided X² Two sided X²
The chi square 
distribution  
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5.411894431 
6.634896601 
10.82756617 
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41.82145620
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3. Results 
3.1 Classical Risk Factors (CRF) and Atrial Fibrillation (AF) 
Some of the studies analysed provided additional data about the relationship between classical risk factors like 
family history of AF, alcohol, smoking, diabetes mellitus, hyperlipidemia, hypertension, previous stroke/TIA, 
arteriosclerosis, congestive heart failure, cardiovascular disease and atrial fibrillation with conflicting results on its 
role as an etiological factor. The data are viewed by Table 2. The hypothesis without CRF no AF was tested. The 
hypothesis if CRF then AF was testet too. In fact, the null-hypothesis alltogether had to be rejected. 
Proof. 
H0: Without family history of AF no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)). 
H0: If family history of AF then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).  
H0: Without alcohol no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).    
H0: If alcohol then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).    
H0: Without smoking no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).   
H0: If smoking then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).    
H0: Without diabetes mellitus no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).  
H0: If diabetes mellitus then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).   
H0: Without dyslipidemia no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).   
H0: If hyperlipidemia then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).   
H0: Without hypertension no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).   
H0: If hypertension then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).   
H0: Without cerbral infarction no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).  
H0: If previous stroke/TIA then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).  
H0: Without arteriosclerosis no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).  
H0: If previous vascular disease then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)). 
H0: Without cong. heart failure no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)). 
H0: If congestive heart failure then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)). 
H0: Without cardiovasc. disease no atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)). 
H0: If cardiovascular disease then atrial fibrillation. (Null hypothesis rejected, no significant result (Table 2)).  
Neither family history of AF nor alcohol nor smoking nor diabetes mellitus nor hyperlipidemia nor hypertension 
nor previous stroke/TIA nor arteriosclerosis nor congestive heart failure nor cardiovascular disease et cetera can be 
regarded as a cause or as the cause of AF. Q. e. d. 
3.1 A therapy with (Methyl) Prednisolone and Atrial Fibrillation(AF) 
Little or none direct information is available on the effect of an anti-viral or anti-inflammatory therapy on the 
reduction of atrial fibrillation. According to Engelmann and Svendsen (Engelmann & Svendsen, 2005) a treatment 
with glucocorticoids seems to reduce AF. The systematic review and meta-analysis of observational studies of Liu 
et al. (Liu et al., 2007) suggests that increased CRP levels are related to greater risk of AF recurrence. Henningsen 
et al. (Henningsen et al., 2009) investigated the role of inflammatory processes in the development of atrial 
fibrillation and were able to provide some evidence that patients with AF had elevated levels of inflammatory 
markers. In general, a low-dose glucocorticoid therapy (i. e. 16 mg methylprednisolone for 4 weeks tapered to 4 
mg for 4 months) compared to placebo should have no effect on (recurrent or permanent) AF. In other words we do 
expect that a therapy with (methyl-) prednisolone and AF are independent of each other. Dernellis & Panaretou 
(Dernellis & Panaretou, 2004) investigated the effect of a low-dose glucocorticoid therapy (16 mg 
methylprednisolone for 4 weeks tapered to 4 mg for 4 months) compared to placebo on AF. According to Dernellis 
& Panaretou (Dernellis & Panaretou, 2004) a therapy with (methyl-) prednisolone was able to reduce recurrent AF 
from 50% in the placebo group to 9.6% in the glucocorticoid group. Furthermore, permanent AF was reduced by a 
therapy with (methyl-) prednisolone from 29% in the placebo group to 2% in the glucocorticoid group. The results 
were significant. The data of the study of Dernellis & Panaretou (Dernellis & Panaretou, 2004) were reanalysed 
(Table 3). 
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Null Hypothesis: 
A therapy with (methyl-) prednisolon does not prevent from permanent AF. In other words, k = 0. 
Alternative Hypothesis: 
A therapy with (methyl-) prednisolon does prevent from permanent AF. In other words, k < 0. 
The significance level (Alpha) below which the null hypothesis will be rejected is alpha=0.05.  
Proof.  
The results of the re-analyses of the data of the study of Dernellis & Panaretou (Dernellis & Panaretou, 2004) 
which investigated the relationship between a low-dose glucocorticoid therapy (i. e. 16 mg methylprednisolone 
for 4 weeks tapered to 4 mg for 4 months) compared to placebo and the reduction of permanent AF are viewed by 
the table (Table 3). Altogether, the data of the study of Dernellis & Panaretou (Dernellis & Panaretou, 2004) 
provide highly significant evidence that a low-dose glucocorticoid therapy (i. e. 16 mg methylprednisolone for 4 
weeks tapered to 4 mg for 4 months) compared to placebo excludes permanent AF (p(Prednisolone excludes AF) 
=0.99038462;  X²(Prednisolone excludes AF) = 0.0204) while the causal relationship was k < 0. In other words, 
the data as published by Dernellis & Panaretou (Dernellis & Panaretou, 2004) are not self-contradictory (Barukčić, 
2018) and can be used for causal analysis too. The causal relationship between a therapy with (methyl) 
prednisolone and permanent AF is k = - 0.3731 while the exact p value (k) calculated by the hypergeometric 
distribution is p value (k) < 0.0001. The 95% CI (k) is -0.5924 until -0.1538, a highly significant result. In other 
words, there is a highly significant causal relationship between a low-dose glucocorticoid therapy (i. e. 16 mg 
methylprednisolone for 4 weeks tapered to 4 mg for 4 months) and the absence of permanent AF. A low-dose 
glucocorticoid therapy is highly effective against permanent AF and an “anti-dot” against permanent AF. Q. e. d.  
4. Discussion 
Much attention has been devoted in the past years to inflammation (Aviles et al., 2003; Anderson et al., 2004;  
Conway et al., 2004; Asselbergs et al., 2005) as the pathophysiological mechanism underlying the genesis of AF 
which has been reinforced even by experimental studies (Kirchhof et al., 2013). Still, the pathogenesis AF remains 
not even partially understood. The pathophysiology of AF is complex, but an inflammation itself can lead to a kind 
of “atrial myocarditis” with subsequent structural atrial changes resulting among other in AF (Korantzopoulos et 
al., 2003). Several case studies support this hypothesis. A 57-year-old patient with rheumatoid arthritis treated 
with a combination of etanercept and methotrexate developed a new-onset of atrial fibrillation after treatment for 
five months on this therapy (Wooten et al., 2000). As long as it appears justified to rely on the data as published by 
Hung et al. (Hung et al., 2017) Etanercept is effective against cytomegalovirus but not for sure against EBV. 
According to Barukčić et al. (Barukčić at al. 2018), EBV is the cause of rheumatoid arthritis (RA). Thus far, 
according to this case, it is highly improbable, that cytomegalovirus is a cause or the cause of atrial fibrillation. The 
incidence of myocarditis as a complication of an EBV infection is not so high (Takano et al., 2008). However, a 
chronic active Epstein-Barr virus (CAEBV) infection characterized by high EBV DNA levels in the peripheral 
blood (Kawabe et al., 2018) can cause organ damage demonstrated by endomyocardial biopsies with lymphocytic 
infiltration, necrosis of cardiomyocytes et cetera and end up in a chronic active myocarditis (Takano et al., 2008). 
Sometimes, an Epstein-Barr myocarditis (Antonakaki et al., 2016) is so severe that an urgent orthotopic heart 
transplantation is necessary. Finally, Aghenta et al. (Aghenta et al., 2008) published the case of a 19-year-old 
healthy male patient presented to hospital with clinical features of infectious mononucleosis (IM). Symptoms 
worsened despite therapy (ibuprofen, intravenous methylprednisolone, intravenous fluids et cetera). On day 2 of 
admission to hospital, electrocardiogram (ECG) showed atrial fibrillation. An Epstein Bar virus infection is able 
to cause a symptomatic atrial fibrillation (Aghenta et al., 2008) as a result of viral invasion. Judged solely in terms 
of logic, one single documented co-occurrence or co-incidence of an Epstein Bar virus infection and atrial 
fibrillation is of course not enough to provide a proof of a cause effect relationship between EBV and AF. It is very 
hard to make any sense of the case reported without supposing that EBV was the cause of AF of this 19-year-old 
healthy male patient. What is further remarkable about this case reported is that AF cannot be regarded any longer 
only as a health problem of those who are older.  
It seems fair to say that the way in which other studies published support the EBV hypothesis with respect to AF is 
seemingly somewhat different. In the following, let us focuses heavily on the articulation and evaluation of some 
impressive rheumatoid arthritis studies. Very roughly, before examining these remarkable achievements in detail, 
to date, data are available which support the hypothesis that patients with rheumatoid arthritis have increased risk 
(Bacani et al., 2015) of atrial fibrillation. The incidence of atrial fibrillation (AF) among patients with rheumatoid 
arthritis (RA) compared to the entire Danish population was increased by a 40% (Lindhardsen et al., 2012). Bacani 
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et al. (Bacani et al., 2015) found that the incidence of AF even after adjustment for AF risk factors is increased in 
patients with RA. Epstein–Barr virus (EBV) is the cause of rheumatoid arthritis (Barukčić at al. 2018). Already we 
are very close to the core of the problem. In the first place, there is only one reasonable explanation for that 
consistency; it is very likely that Epstein–Barr virus (EBV) and atrial fibrillation are causally related. One 
difficulty with such an interpretation is of course even a relationship between EBV and RA is highly probable the 
same is not proved at a certain level of significance and it is necessary and good practice to stay calm and patient on 
this topic.  
The Epstein–Barr virus (EBV) was discovered by electron microscopy of cells cultured from Burkitt's lymphoma 
tissue by Epstein et al. (Epstein et al., 1964) Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a 
gamma herpes virus which infects a large fraction of the human population. After the primary infection, EBV 
persists for life (Cohen, 2000) in memory B cells in the peripheral blood of human host while well controlled by 
host’s immune system.  
There is currently no treatment for removing EBV infections and very little success treating EBV infection with 
drugs. Corticosteroids are sometimes helpful. In the excellent paper, Dernellis and Panaretou (Dernellis & 
Panaretou, 2004) demonstrated that the use of low-dose Methylprednisolone successfully prevents recurrent and 
permanent AF. 
Cell culture experiments support the thesis that Vitamin D may reduce the severity of viral infection by suppressing 
inflammation (Beardb et al., 2011). 
Acyclovir with limited gastrointestinal absorption had no significant effect on EBV-related symptoms (Bissell et 
al., 1980) while Valacyclovir treatment in Epstein-Barr virus infection was effective (Lerner et al., 2007). 
Valacyclovir inhibits EBV thymidine kinase and is absorbed more efficiently from the gastrointestinal tract than 
acyclovir. Valacyclovir was not able to reduce infant CMV acquisition or breastmilk shedding of cytomegalovirus 
(Roxby et al., 2014) while EBV reactivation was decreased with valganciclovir prophylaxis (Gill et al., 2014). 
The direct anti-viral activity of ascorbic acid (vitamin C, ascorbate) against herpes simplex virus type 1, influenza 
virus type A, picornaviridea virus 1, herpes simplex viruses (types 1 and 2), cytomegalovirus, parainfluenza virus 
type 2 and other viruses are documented in vitro (Furuya et al., 2008). Vitamin C deficiency is associated with viral 
infections (Chen et al., 2009). The clinical study of (Mikirova & Hunninghake, 2014) demonstrated that an 
intravenous administration of high dose ascorbate (IVC) therapy according to Riordan IVC protocol (Riordan et al., 
2003; Mikirova et al., 2013) is able to reduce EBV EA IgG and EBV VCA IgM antibody levels over time. 
High-dose IVC infusions at the 7.5, 15, 25, and 50 gram dosages adjusted by plasma ascorbic acid levels attained 
post infusion and patients’ tolerance lead to hemolysis in patients with glucose-6-phosphate dehydrogenase 
(G6PD) deficiency. Adding magnesium to high-dose IVC ascorbate infusions can help to reduce incidence of vein 
irritation and spasm. 
Zinc (Zn) play a very important role in human immune system because of its pivotal role in the efficiency of 
modulating immune function (Mocchegiani & Muzzioli, 2000; Hirano et al., 2008). Zinc-deficient patients 
experience increased susceptibility to a variety of pathogens (Shankar & Prasad, 1998). Zinc supplementation may 
increase host resistance to infections. Arens and Travis (Arens and Travis, 2000) were able to inactivate herpes 
simplex virus (HSV) with zinc salts. 
Despite good progress in the management of atrial fibrillation, AF remains one of the major causes of sudden death 
and morbidity in the world. For the patient, AF is associated with severe consequences such as stroke or death and 
other, while the direct costs of AF for the society are already extraordinary high (Stewart et al., 2004; Kim et al., 
2011). In the year 2011, the US-AF costs have been estimated to range from $6.0 to $26.0 billion (Kim et al., 2011). 
The complexity underlying AF and the relative inefficacy of the currently available pharmacotherapy against AF 
requires and justifies the development of new treatment strategies to try to cure AF (Table 6). 
5. Conclusion 
Given the complexity of AF pathophysiology the findings of this study provide evidence of an impact of EBV 
infection on atrial fibrillation. Undoubtedly, the hypothesis: without EBV infection no AF remains to be elucidated 
and more systematic, regional studies of AF are required to better understand the relationship between an EBV 
infection and AF. At first sight, it seems hard to find one single patient with AF with a negative EBV serology. 
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Table 6. Therapeutic schema to cure atrial fibrillation (experimental; not verified by trials; Don’t use without 
doctor’s advise!!!) 
Drug (Methyl-) prednisolon Cimetidin Valacyclovir Zinc-histidine Vitamin C Vitamin D  20.000 I. U. 
Milk thistle
(silymarin) 
Dosage 40 mg 1-0-0 a.c. 400 mg 1-0-1 500 mg 1-0-1 15 mg  0-1-0 1 g  0-1-0 1x1 per week  ca. 400 mg  
0-1-0 daily 
Week (on 5 days per week) a.c./c.c. plus a lot of water !!! p.c. c.c./p.c. (i.e. Sundays)  
1 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
2 - x x (7 days) x x x x 
3 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
4 - x x (7 days) x x x x 
5 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
6 - x x (7 days) x x x x 
7 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
8 - x x (7 days) x x x x 
9 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
12 - x x (7 days) x x x x 
11 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
12 - x x (7 days) x x x x 
13 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
14 - x x (7 days) x x x x 
15 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
16 - x x (7 days) x x x x 
17 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
18 - x x (7 days) x x x x 
19 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
20 - x x (7 days) x x x x 
21 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
22 - x x (7 days) x x x x 
23 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
24 - x x (7 days) x x x x 
26 x (Mo, Tue, Wen, Thur, Fri) x - x x x x 
26 - x x (7 days) x x x x 
The drugs taken are cancelled. “x” denotes the necessity of taking the drug, “-” denotes the necessity not to take the 
drug. Start of therapy on. 
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